

REMARKS

Applicant submits this Amendment to indicate the insertion point for the Sequence Listing filed concurrently herewith. Application respectfully requests examination on the merits of this application.

Respectfully submitted,

By _____

Stephen B. Maebius
Attorney for Applicant
Registration No. 35,264

Date July 5, 2001
FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5569
Facsimile: (202) 672-5399

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Marked up replacementTables:

Table 3

		FRI		CDRI		FR2
		1	2	3		4
AHM	<u>(SEQ ID NO: 130)</u>	12345678901234567890123		45678901234		567890123456789
HuSG	I <u>(SEQ ID NO: 131)</u>	DIVMTQSHKFMSTVGDRVSI	TCA	KASQDVNTAVA		WYQQKPGQSPKLLIY
REI	<u>(SEQ ID NO: 132)</u>	DIQMTQSPSSLASAVGDRV	ITC			WYQQKPGKAPKLLIY
RVLa	<u>(SEQ ID NO: 133)</u>	DIQMTQSPSSLASAVGDRV	ITC			WYQQKPGKAPKLLIY
RVlb	<u>(SEQ ID NO: 134)</u>	-----		-----		-----
		CDR2		FR3		
		5		6	7	8
AHM	<u>(SEQ ID NO: 130)</u>	0123456		78901234567890123456789012345678		
HuSG	I <u>(SEQ ID NO: 131)</u>	SASNRYT		GVPDRITGSGSGTDFTFTI	SSVQAEDLALYYC	
REI	<u>(SEQ ID NO: 132)</u>	-----		GVPSRFSGSGSGTDFTLTI	SSLQPEDFATYYC	
RVLa	<u>(SEQ ID NO: 133)</u>	-----		GVPSRFSGSGSGTDFTFTI	SSLQPEDIATYYC	
RVlb	<u>(SEQ ID NO: 134)</u>	-----		-----	Y-----	-----
		CDR3		FR4		
		9		10		
AHM	<u>(SEQ ID NO: 130)</u>	901234567		8901234567		
HuSG	I <u>(SEQ ID NO: 131)</u>	QQHYSTPFT		FGSGTKLEIK		
REI	<u>(SEQ ID NO: 132)</u>	-----		FGQGTKVEIK		
RVLa	<u>(SEQ ID NO: 133)</u>	-----		FGQGTKVEIK		
RVlb	<u>(SEQ ID NO: 134)</u>	-----		-----		

Table 4

		FRI		CDR1		FR2
		1	2	3		4
AHM	<u>(SEQ ID NO: 135)</u>	123456789012345678901234567890		12345		67890123456789
HuSGI	<u>(SEQ ID NO: 136)</u>	QVQLQQSGAELARPGASV	KL	PYWMQ		WVKQRPGQGLEWIG
HG3	<u>(SEQ ID NO: 137)</u>	QVQLQSGAD	VKPGXSVX			WVRQAPGXGLDWVG
RVHa	<u>(SEQ ID NO: 138)</u>	QVQLQSGAEV	KV			WVRQAPGQGLEWMG
RVHb	<u>(SEQ ID NO: 139)</u>	-----T		-----		-----
RVHc	<u>(SEQ ID NO: 140)</u>	-----T		-----		-----
RVHd	<u>(SEQ ID NO: 141)</u>	-----T		-----		-----
RVHe	<u>(SEQ ID NO: 142)</u>	-----T		-----		-----
RVHf	<u>(SEQ ID NO: 143)</u>	-----T		-----		-----
RVHg	<u>(SEQ ID NO: 144)</u>	-----T		-----	R	-----
RVhh	<u>(SEQ ID NO: 145)</u>	-----T		-----		-----
RVhi	<u>(SEQ ID NO: 146)</u>	-----T		-----		-----
RVhj	<u>(SEQ ID NO: 147)</u>	-----T		-----		-----
RVhk	<u>(SEQ ID NO: 148)</u>	-----T		-----		-----
RVhl	<u>(SEQ ID NO: 149)</u>	-----T		-----		-----
RVhm	<u>(SEQ ID NO: 150)</u>	-----T		-----		-----
RVhn	<u>(SEQ ID NO: 151)</u>	-----T		-----		-----

RVHo	<u>(SEQ ID NO: 152)</u>
RVHp	<u>(SEQ ID NO: 153)</u>
RVHq	<u>(SEQ ID NO: 154)</u>
RVHr	<u>(SEQ ID NO: 155)</u>

-----	T	-----	-----
-----	T	-----	-----
-----	T	-----	-----
-----	T	-----	-----

Table 5

AHM	<u>(SEQ ID NO: 156)</u>
HuSGI	<u>(SEQ ID NO: 157)</u>
HG3	<u>(SEQ ID NO: 158)</u>
RVHa	<u>(SEQ ID NO: 159)</u>
RVHb	<u>(SEQ ID NO: 160)</u>
RVHc	<u>(SEQ ID NO: 161)</u>
RVHd	<u>(SEQ ID NO: 162)</u>
RVHe	<u>(SEQ ID NO: 163)</u>
RVHf	<u>(SEQ ID NO: 164)</u>
RVHg	<u>(SEQ ID NO: 165)</u>
RVHh	<u>(SEQ ID NO: 166)</u>
RVHi	<u>(SEQ ID NO: 167)</u>
RVHj	<u>(SEQ ID NO: 168)</u>
RVHk	<u>(SEQ ID NO: 169)</u>
RVHl	<u>(SEQ ID NO: 170)</u>
RVHm	<u>(SEQ ID NO: 171)</u>
RVHn	<u>(SEQ ID NO: 172)</u>
RVHo	<u>(SEQ ID NO: 173)</u>
RVHp	<u>(SEQ ID NO: 174)</u>
RVHq	<u>(SEQ ID NO: 175)</u>
RVHr	<u>(SEQ ID NO: 176)</u>

CDR2	FR3			
5	6	7	8	9
012A3456789012345	SIFPGDGDTRYSQKFKG	67890123456789012ABC345678901234		
-----	-----	KATLTADKSSSTAYMQLSILAFEDSAVYYCAR		
-----	-----	RVTXTDXSXNTAYMELSSLRSEDTAVYYCAR		
-----	-----	RVTMTRDTSTSTVYMELSSLRSEDTAVYYCAR		
-----	-----	-----A-----		
-----	-----	K----A-----		
-----	-----	-----A-----K-----		
-----	-----	K----A-----K-----		
-----	-----	-----A-----L-----A-----		
-----	-----	-----A-----L-----A-----S-----A-----		
-----	-----	-----A-----		
-----	-----	K----A-----S-----A-----		
-----	-----	K----A-----S-----A-----AF-----		
-----	-----	KA-L-A-----S-----A-----		
-----	-----	K----A-----S==A-----Q-----		
-----	-----	K----A-----S-----A-----Q-----1-----		
-----	-----	K----A-----S-----A-----Q-----1-----S-----		
-----	-----	K----A-----S-----A-----1-----		
-----	-----	K----A-----S-----A-----S-----		
-----	-----	-----A-----A-----		
-----	-----	-----A-----S-----		
-----	-----	-----A-----K-----A-----		

Table 6

AHM	<u>(SEQ ID NO: 177)</u>
HuSGI	<u>(SEQ ID NO: 178)</u>
HG3	<u>(SEQ ID NO: 179)</u>
RVHa	<u>(SEQ ID NO: 180)</u>
RVHb	<u>(SEQ ID NO: 181)</u>
RVHc	<u>(SEQ ID NO: 182)</u>
RVHd	<u>(SEQ ID NO: 183)</u>
RVHe	<u>(SEQ ID NO: 184)</u>
RVHf	<u>(SEQ ID NO: 185)</u>
RVHg	<u>(SEQ ID NO: 186)</u>
RVHh	<u>(SEQ ID NO: 187)</u>
RVHi	<u>(SEQ ID NO: 188)</u>
RVHj	<u>(SEQ ID NO: 189)</u>
RVHk	<u>(SEQ ID NO: 190)</u>
RVHl	<u>(SEQ ID NO: 191)</u>
RVHm	<u>(SEQ ID NO: 192)</u>
RVHn	<u>(SEQ ID NO: 193)</u>
RVHo	<u>(SEQ ID NO: 194)</u>
RVHp	<u>(SEQ ID NO: 195)</u>
RVHq	<u>(SEQ ID NO: 196)</u>
RVHr	<u>(SEQ ID NO: 197)</u>

CDR3	FR4
10	11
57890ABJK12	34567890123
GLRRGGYYFDY	WGQGTTLVSS
-----	WGQGTLTVSS
-----	WGQGTTVTVSS
-----	-----
-----	-----
-----	-----
-----	-----
-----	-----
-----	-----
-----	-----
-----	-----
-----	-----
-----	-----
-----	-----
-----	-----
-----	-----
-----	-----
-----	-----
-----	-----
-----	-----
-----	-----
-----	-----
-----	-----
-----	-----
-----	-----
-----	-----
-----	-----
-----	-----
-----	-----

Design of V region of Natural Humanized Antibody

A) L chain	FR1				CDR1				FR2				CDR2			
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	
HM1.24 (SEQ ID NO: 130)	12345678901234567890123		45678901234		567890123456789											
HuSG I (SEQ ID NO: 131)	DIVMTQSHKFMSTSVDGRVSITC		KASQDVNTAVA		WYQQKPGQSPKLLIY											
REI (SEQ ID NO: 132)	DIQMTQSPSSLSASVYGDRTITC				WYQQKPGKAPKLLIY											
Primary design (RVLa (SEQ ID NO: 133))	DIQMTQSPSSLSASVYGDRTITC				WYQQKPGKAPKLLIY											
Secondary design (SEQ ID NO: 133)	-----		-----		-----		-----		-----		-----		-----		-----	
B) H chain	FR3				CDR1				FR2				CDR2			
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	
HM1.24 (SEQ ID NO: 130)	78901234567890123456789012345678		901234567VA		8901234567											
HuSG I (SEQ ID NO: 131)	GVPDRITGSQSGTDFITFISSVQAEDLALYYC		QHQHYSPTFT		FGSGTGLEIK											
REI (SEQ ID NO: 132)	GVPSRFGSGSGTDFITLISSLOPEDATYYC				FGQGTRKVEIK											
Primary design (RVLa (SEQ ID NO: 133))	GVPSRFGSGSGTDFITLISSLOPEDATYYC				FGQGTRKVEIK											
Secondary design (SEQ ID NO: 133)	-----		-----		-----		-----		-----		-----		-----		-----	

Design of V region of Natural Humanized Antibody

B) H chain	FR1				CDR1				FR2				CDR2			
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	
HM1.24 (SEQ ID NO: 198)	123456789012345678901234567890		12345678901234567890		12345											
HuSG I (SEQ ID NO: 199)	QVQLQQSGAELARPGASVVKLSCKASGYFT		QVQLQQSGAELARPGASVVKLSCKASGYFT		QVQLQQSGAELARPGASVVKLSCKASGYFT											
HG3 (SEQ ID NO: 200)	EVQLVQSGADVKPKGXSVXSVCKASGYFS		EVQLVQSGADVKPKGXSVXSVCKASGYFS		EVQLVQSGADVKPKGXSVXSVCKASGYFS											
Primary design (RVHr (SEQ ID NO: 201))	QVQLVQSGAEVVKPGASVVKSVCKASGYFN		QVQLVQSGAEVVKPGASVVKSVCKASGYFN		QVQLVQSGAEVVKPGASVVKSVCKASGYFN											
Secondary design (2NDrvh (SEQ ID NO: 202))	-----		-----		-----		-----		-----		-----		-----		-----	
B) H chain	FR3				CDR3				FR2				CDR2			
	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	
HM1.24 (SEQ ID NO: 198)	67890123456789012ABC345678901234		57890ABJK12		34567890123											
HuSG I (SEQ ID NO: 199)	KATLTDKSSSTAYMQLSILAFEDSAVYYCAR		GLRRGGYYFDY		WGOGTTLTVSS											
HG3/JH6 (SEQ ID NO: 200)	RVTXTDXSXNTAYMELSSLRSEDTAVYYCAR		WGQGTTVTVSS													

Attv Dkt No 053166/0271

WGOGTTTIVVSS

Primary design $\frac{(\text{RVLa/Hr})}{(\text{2}^{\text{nd}} \text{ RVH})}$
 Secondary design $\frac{(\text{RVLa/Hr})}{(\text{2}^{\text{nd}} \text{ RVH})}$

002.604991.1

Marked up page 74 line 23.

FR3 of primary design antibody (SEQ ID NO: 203)